An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bicycle Therapeutics (NASDAQ: BCYC) announces the acceptance of two abstracts for poster presentation at the 2024 ASCO Annual Meeting. The abstracts focus on the evaluation of clinical pharmacokinetics and safety of Bicycle Toxin Conjugates, as well as a phase 2/3 study targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer.
Bicycle Therapeutics (NASDAQ: BCYC) annuncia l'accettazione di due abstract per la presentazione poster al Meeting Annuale dell'ASCO 2024. Gli abstract si concentrano sulla valutazione della farmacocinetica clinica e della sicurezza dei Coniugati Tossinici di Bicycle, nonché su uno studio di fase 2/3 che mira al Nectin-4 in pazienti con cancro uroteliale localmente avanzato o metastatico.
Bicycle Therapeutics (NASDAQ: BCYC) anuncia la aceptación de dos resúmenes para presentación en póster en la Reunión Anual de ASCO 2024. Los resúmenes se centran en la evaluación de la farmacocinética clínica y la seguridad de los Conjugados Tóxicos de Bicycle, así como en un estudio de fase 2/3 dirigido a Nectin-4 en pacientes con cáncer urotelial localmente avanzado o metastásico.
바이시클 테라퓨틱스 (NASDAQ: BCYC)가 2024년 ASCO 연례 회의에서 포스터 발표를 위해 두 개의 초록이 수락되었다고 발표했습니다. 이 초록들은 바이시클 독소 접합체의 임상 약동학 및 안전성 평가와 국소적으로 진행되거나 전이된 요로상피암 환자를 대상으로 한 Nectin-4를 목표로 하는 2/3상 연구에 초점을 맞추고 있습니다.
Bicycle Therapeutics (NASDAQ: BCYC) annonce l'acceptation de deux abstracts pour une présentation par affiche lors de la Réunion Annuelle de l'ASCO 2024. Ces abstracts se concentrent sur l'évaluation de la pharmacocinétique clinique et de la sécurité des conjugués toxiques de Bicycle, ainsi que sur une étude de phase 2/3 ciblant Nectin-4 chez des patients atteints de cancer urothélial localement avancé ou métastatique.
Bicycle Therapeutics (NASDAQ: BCYC) gibt die Annahme von zwei Abstracts für Posterpräsentationen auf der Jahrestagung der ASCO 2024 bekannt. Die Abstracts befassen sich mit der Bewertung der klinischen Pharmakokinetik und Sicherheit von Bicycle Toxin Konjugaten sowie einer Phase-2/3-Studie, die Nectin-4 bei Patienten mit lokal fortgeschrittenem oder metastasiertem Urothelkrebs abzielt.
Positive
None.
Negative
None.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago.
Poster Presentation Details:
Title: Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of Bicycle Toxin Conjugates (BTCs)
PosterSession Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Date and Time: Saturday, June 1, at 9 a.m. CT
Abstract Number: 3088
Speaker/Lead Author: Justin Bader, Pharm.D., MBA, Bicycle Therapeutics
Title: A phase 2/3 study of Bicycle Toxin Conjugate BT8009 targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2
PosterSession Title: Genitourinary Cancer – Kidney and Bladder
Date and Time: Sunday, June 2, at 9 a.m. CT
Abstract Number: TPS4619
Speaker/Lead Author: Yohann Loriot, M.D., Ph.D., Institut de Cancérologie Gustave Roussy, Université Paris-Saclay
The posters will be made available in the Publications section of bicycletherapeutics.com following the presentations.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.
What is the significance of Bicycle Therapeutics announcing two abstracts accepted for presentation at the 2024 ASCO Annual Meeting?
The abstracts focus on evaluating the clinical pharmacokinetics and safety of Bicycle Toxin Conjugates, as well as a phase 2/3 study targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer.
When and where will the poster presentations take place for Bicycle Therapeutics at the 2024 ASCO Annual Meeting?
The poster presentations are scheduled for June 1 at 9 a.m. CT and June 2 at 9 a.m. CT in Chicago.
Who are the lead authors for the abstracts presented by Bicycle Therapeutics at the 2024 ASCO Annual Meeting?
Justin Bader, Pharm.D., MBA, and Yohann Loriot, M.D., Ph.D., are the lead authors for the abstracts.
Where can the posters from the presentations be accessed?
The posters will be available on bicycletherapeutics.com in the Publications section after the presentations.
Bicycle Therapeutics plc American Depositary Shares
bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
